EP3062795A4 - Kristalline formen therapeutischer verbindungen und verwendungen davon - Google Patents

Kristalline formen therapeutischer verbindungen und verwendungen davon Download PDF

Info

Publication number
EP3062795A4
EP3062795A4 EP14857110.2A EP14857110A EP3062795A4 EP 3062795 A4 EP3062795 A4 EP 3062795A4 EP 14857110 A EP14857110 A EP 14857110A EP 3062795 A4 EP3062795 A4 EP 3062795A4
Authority
EP
European Patent Office
Prior art keywords
crystalline forms
therapeutic compounds
therapeutic
compounds
crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP14857110.2A
Other languages
English (en)
French (fr)
Other versions
EP3062795A1 (de
Inventor
Elizabeth ENLOW
Minh Ngoc Nguyen
Winston Z. ONG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kala Bio Inc
Original Assignee
Kala Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/184,886 external-priority patent/US9353123B2/en
Application filed by Kala Pharmaceuticals Inc filed Critical Kala Pharmaceuticals Inc
Publication of EP3062795A1 publication Critical patent/EP3062795A1/de
Publication of EP3062795A4 publication Critical patent/EP3062795A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dispersion Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
EP14857110.2A 2013-11-01 2014-11-03 Kristalline formen therapeutischer verbindungen und verwendungen davon Withdrawn EP3062795A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361898741P 2013-11-01 2013-11-01
US14/184,886 US9353123B2 (en) 2013-02-20 2014-02-20 Therapeutic compounds and uses thereof
PCT/US2014/063630 WO2015066584A1 (en) 2013-11-01 2014-11-03 Crystalline forms of therapeutic compounds and uses thereof

Publications (2)

Publication Number Publication Date
EP3062795A1 EP3062795A1 (de) 2016-09-07
EP3062795A4 true EP3062795A4 (de) 2017-05-31

Family

ID=53005242

Family Applications (1)

Application Number Title Priority Date Filing Date
EP14857110.2A Withdrawn EP3062795A4 (de) 2013-11-01 2014-11-03 Kristalline formen therapeutischer verbindungen und verwendungen davon

Country Status (5)

Country Link
EP (1) EP3062795A4 (de)
JP (2) JP6426195B2 (de)
AU (1) AU2014341966B2 (de)
CA (2) CA2928665A1 (de)
WO (1) WO2015066584A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6426195B2 (ja) * 2013-11-01 2018-11-21 カラ ファーマシューティカルズ インコーポレイテッド 治療用化合物の結晶形態及びその使用
US11957669B2 (en) 2017-08-11 2024-04-16 Amorepacific Corporation Pharmaceutical composition containing (R)-N-[1-(3,5-difluoro-4-methansulfonylamino-phenyl)-ethyl]-3-(2-propyl-6-trifluoromethyl-pyridin-3-yl)-acrylamide
WO2020179837A1 (en) 2019-03-04 2020-09-10 Ricoh Company, Ltd. Cooperation processing apparatus and method
GB201915447D0 (en) * 2019-10-24 2019-12-11 Johnson Matthey Plc Polymorphs of avapritinib and methods of preparing the polymorphs

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014130612A1 (en) * 2013-02-20 2014-08-28 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE482946T1 (de) * 1999-02-10 2010-10-15 Astrazeneca Ab Chinazolinderivate als angiogenesehemmer und zwischenprodukte dafür
PL371486A1 (en) * 2002-02-01 2005-06-13 Astrazeneca Ab Quinazoline compounds
CL2004000409A1 (es) * 2003-03-03 2005-01-07 Vertex Pharma Compuestos derivados de 2-(cilo sustituido)-1-(amino u oxi sustituido)-quinazolina, inhibidores de canales ionicos de sodio y calcio dependientes de voltaje; composicion farmaceutica; y uso del compuesto en el tratamiento de dolor agudo, cronico, neu
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
GB0330002D0 (en) * 2003-12-24 2004-01-28 Astrazeneca Ab Quinazoline derivatives
EP1802608A1 (de) * 2004-10-12 2007-07-04 AstraZeneca AB Chinazolinderivate zum einsatz gegen krebs
JP6426195B2 (ja) * 2013-11-01 2018-11-21 カラ ファーマシューティカルズ インコーポレイテッド 治療用化合物の結晶形態及びその使用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014130612A1 (en) * 2013-02-20 2014-08-28 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CAIRA: "Crystalline Polymorphism of Organic Compounds", TOPICS IN CURRENT CHEMISTRY, SPRINGER, BERLIN, DE, vol. 198, January 1998 (1998-01-01), pages 163 - 208, XP008166276, ISSN: 0340-1022 *
See also references of WO2015066584A1 *

Also Published As

Publication number Publication date
JP2019038824A (ja) 2019-03-14
AU2014341966B2 (en) 2017-08-17
WO2015066584A1 (en) 2015-05-07
AU2014341966A1 (en) 2016-05-12
CA2928665A1 (en) 2015-05-07
JP2016535779A (ja) 2016-11-17
JP6426195B2 (ja) 2018-11-21
EP3062795A1 (de) 2016-09-07
CA3109285A1 (en) 2015-05-07

Similar Documents

Publication Publication Date Title
IL287516A (en) Medicinal uses of empagliflozin
HRP20190101T1 (hr) Terapeutske uporabe empagliflozina
EP3046563A4 (de) Substituierte aminopyrimidinverbindungen und verfahren zur verwendung
EP3019483A4 (de) Therapeutische wirkstoffverbindungen und deren verfahren zur verwendung
EP3073999A4 (de) Kristalline form i von ibrutinib
HK1213818A1 (zh) 依帕列淨的治療用途
EP3027193A4 (de) Therapeutische wirkstoffverbindungen und deren verfahren zur verwendung
EP3062618A4 (de) Kristalline formen therapeutischer verbindungen und verwendungen davon
EP3083589A4 (de) Substituierte piperazinverbindungen und verfahren zur verwendung davon
LT2981271T (lt) Empagliflozino terapinis panaudojimas
EP3038622A4 (de) Heterocyclische verbindungen und verfahren zur verwendung
EP3054974A4 (de) Glycaninteragierende verbindungen und verfahren zur verwendung
EP2983681A4 (de) Therapeutische zusammensetzungen und verwendungen davon
EP3019477A4 (de) Heterocyclische verbindungen und verfahren zu deren verwendung
EP3036226A4 (de) Hemmer der humanen 12/15-lipoxygenase
EP3068416A4 (de) Therapeutische verbindungen aus kava und verfahren zur verwendung davon
EP3049079A4 (de) Feste formen von ceftolozan
EP3055281A4 (de) Herstellung von hydroxy-benzylbenzen-derivaten
EP3050881A4 (de) Neuartiges a-naphthyl-harnstoff-derivat und medizinische anwendung davon
EP3062795A4 (de) Kristalline formen therapeutischer verbindungen und verwendungen davon
EP3027182A4 (de) Neuartiges kupfercysteamin und verfahren zur verwendung
EP3104869A4 (de) Schmerzbehandlung
EP3027607A4 (de) Substituierte heteroarylverbindungen und verfahren zur verwendung davon
EP2986309A4 (de) Peptidverbindungen und verfahren zur herstellung und verwendung davon
EP3052475A4 (de) Pharmazeutische verwendung von 3-benzylsulfonyl-propionitril

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20160601

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20170504

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/10 20060101ALI20170426BHEP

Ipc: C07D 493/10 20060101ALI20170426BHEP

Ipc: A61K 31/517 20060101AFI20170426BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1228278

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20180604

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20181215